Difference between revisions of "Abiraterone (Zytiga)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(updated content)
m (updated content)
Line 1: Line 1:
 
==General information==
 
==General information==
Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor.  Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.<ref name="insert">[http://www.zytiga.com/downloads/full_product_information.pdf Abiraterone (Zytiga) package insert]</ref><ref>[[Media:Abiraterone.pdf | Abiraterone (Zytiga) package insert (locally hosted backup)]]</ref><ref>[http://www.zytiga.com/ Zytiga manufacturer's website]</ref>
+
Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor, CYP17 inhibitor.  Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.<ref name="insert">[http://www.zytiga.com/sites/default/files/pdf/full_product_information.pdf Abiraterone (Zytiga) package insert]</ref><ref>[[Media:Abiraterone.pdf | Abiraterone (Zytiga) package insert (locally hosted backup)]]</ref><ref>[http://www.zytiga.com/ Zytiga manufacturer's website]</ref>
 
<br>Route: PO
 
<br>Route: PO
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
Line 10: Line 10:
  
 
==Patient drug information==
 
==Patient drug information==
*[http://www.zytiga.com/downloads/full_product_information.pdf#page=8 Abiraterone (Zytiga) package insert PDF pages 8-9]<ref name="insert"></ref>
+
*[http://www.zytiga.com/sites/default/files/pdf/full_product_information.pdf#page=8 Abiraterone (Zytiga) package insert PDF pages 8-9]<ref name="insert"></ref>
 
*[http://www.chemocare.com/chemotherapy/drug-info/abiraterone-acetate.aspx Abiraterone (Zytiga) patient drug information (Chemocare)]<ref>[http://www.chemocare.com/chemotherapy/drug-info/abiraterone-acetate.aspx Abiraterone (Zytiga) patient drug information (Chemocare)]</ref>
 
*[http://www.chemocare.com/chemotherapy/drug-info/abiraterone-acetate.aspx Abiraterone (Zytiga) patient drug information (Chemocare)]<ref>[http://www.chemocare.com/chemotherapy/drug-info/abiraterone-acetate.aspx Abiraterone (Zytiga) patient drug information (Chemocare)]</ref>
 
*[http://www.zytigaone.com ZytigaOne patient support resources]<ref>[http://www.zytigaone.com ZytigaOne patient support resources]</ref>
 
*[http://www.zytigaone.com ZytigaOne patient support resources]<ref>[http://www.zytigaone.com ZytigaOne patient support resources]</ref>

Revision as of 03:32, 5 April 2014

General information

Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor, CYP17 inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 4/28/2011: FDA approved "to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy)."
  • 12/10/2012: FDA approved "to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy."

Also known as

Abiraterone acetate.

References